Literature DB >> 8289783

Retinoic acid represses Oct-3/4 gene expression through several retinoic acid-responsive elements located in the promoter-enhancer region.

E Pikarsky1, H Sharir, E Ben-Shushan, Y Bergman.   

Abstract

The Oct-3/4 gene product, which belongs to the POU family of transcription factors, is a good candidate for regulating initial differentiation decisions. It is expressed in the earliest stages of embryogenesis and repressed in subsequent stages. Retinoic acid (RA)-induced differentiation of embryonal carcinoma (EC) cells is accompanied by decreased expression of the Oct-3/4 gene. Previous findings show that sequences in the Oct-3/4 enhancer region (designated RARE1) are targets for RA-mediated repression (H. Okazawa, K. Okamoto, F. Ishino, T. Ishino-Kaneko, S. Takeda, Y. Toyoda, M. Muramatsu, and H. Hamada, EMBO J. 10:2997-3005, 1991). Our present results demonstrate conclusively that the TATA-less Oct-3/4 promoter is also a target for RA-induced repression. We identified a novel cis element in the Oct-3/4 promoter harbors a putative Sp1 binding site and a RA-responsive element (designated RAREoct), which are juxtaposed to one another. Protein binding to the Sp1 site is independent of protein binding to the RAREoct sequence. Unlike the RARE1 situated in the Oct-3/4 enhancer which does not contain a typical RAR recognition site, the RAREoct identified in this study consists of three directly repeated motifs that exhibit extensive homology to RARE sequences located in RA-responsive genes. Moreover, the RAREoct shows different DNA-binding characteristics and DNase I footprint patterns with nuclear proteins isolated from undifferentiated versus RA-differentiated EC cells. This suggests that the RAREoct element binds different nuclear proteins in RA-treated and untreated EC cells which most probably belong to the RA receptor, retinoid X receptor, or orphan receptor families of transcription factors. Using site-directed mutagenesis, we show that the RAREoct contributes to the transcriptional activation of Oct-3/4 promoter in P19 cells and, most interestingly, mediates the RA-induced repression in RA-differentiated EC cells. Thus, the RAREoct element could be one of the points of integration of several signalling pathways influencing Oct-3/4 expression. In accordance with the suggestion that suppression of Oct-3/4 expression is a crucial step during embryogenesis, the Oct-3/4 upstream region contains multiple targets for RA-induced repression, probably to ensure accurate and prompt repression of Oct-3/4 expression. It is possible that these repressors are differentially used at specific stages of development in response to various signals.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8289783      PMCID: PMC358458          DOI: 10.1128/mcb.14.2.1026-1038.1994

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  59 in total

Review 1.  Retinoid receptors in vertebrate limb development.

Authors:  C Mendelsohn; E Ruberte; P Chambon
Journal:  Dev Biol       Date:  1992-07       Impact factor: 3.582

2.  Improved expression vectors for eukaryotic promoter/enhancer studies.

Authors:  J L Fridovich-Keil; J M Gudas; I B Bryan; A B Pardee
Journal:  Biotechniques       Date:  1991-11       Impact factor: 1.993

3.  RAR gamma 2 expression is regulated through a retinoic acid response element embedded in Sp1 sites.

Authors:  J M Lehmann; X K Zhang; M Pfahl
Journal:  Mol Cell Biol       Date:  1992-07       Impact factor: 4.272

4.  Repression by ARP-1 sensitizes apolipoprotein AI gene responsiveness to RXR alpha and retinoic acid.

Authors:  R L Widom; M Rhee; S K Karathanasis
Journal:  Mol Cell Biol       Date:  1992-08       Impact factor: 4.272

5.  Retinoic acid-dependent transactivation of major histocompatibility complex class I promoters by the nuclear hormone receptor H-2RIIBP in undifferentiated embryonal carcinoma cells.

Authors:  T Nagata; J H Segars; B Z Levi; K Ozato
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-01       Impact factor: 11.205

6.  Characterization of three RXR genes that mediate the action of 9-cis retinoic acid.

Authors:  D J Mangelsdorf; U Borgmeyer; R A Heyman; J Y Zhou; E S Ong; A E Oro; A Kakizuka; R M Evans
Journal:  Genes Dev       Date:  1992-03       Impact factor: 11.361

7.  Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors.

Authors:  X K Zhang; B Hoffmann; P B Tran; G Graupner; M Pfahl
Journal:  Nature       Date:  1992-01-30       Impact factor: 49.962

8.  Antagonism between apolipoprotein AI regulatory protein 1, Ear3/COUP-TF, and hepatocyte nuclear factor 4 modulates apolipoprotein CIII gene expression in liver and intestinal cells.

Authors:  M Mietus-Snyder; F M Sladek; G S Ginsburg; C F Kuo; J A Ladias; J E Darnell; S K Karathanasis
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

9.  A transferable silencing domain is present in the thyroid hormone receptor, in the v-erbA oncogene product and in the retinoic acid receptor.

Authors:  A Baniahmad; A C Köhne; R Renkawitz
Journal:  EMBO J       Date:  1992-03       Impact factor: 11.598

10.  H-2RIIBP (RXR beta) heterodimerization provides a mechanism for combinatorial diversity in the regulation of retinoic acid and thyroid hormone responsive genes.

Authors:  M S Marks; P L Hallenbeck; T Nagata; J H Segars; E Appella; V M Nikodem; K Ozato
Journal:  EMBO J       Date:  1992-04       Impact factor: 11.598

View more
  35 in total

1.  Impaired neural differentiation potency by retinoic acid receptor-α pathway defect in induced pluripotent stem cells.

Authors:  Pei-Shan Hou; Wen-Chin Huang; Wei Chiang; Wei-Che Lin; Chung-Liang Chien
Journal:  Cell Reprogram       Date:  2014-11-03       Impact factor: 1.987

2.  Retinoic acid orchestrates fibroblast growth factor signalling to drive embryonic stem cell differentiation.

Authors:  Marios P Stavridis; Barry J Collins; Kate G Storey
Journal:  Development       Date:  2010-03       Impact factor: 6.868

3.  Transcriptional regulation of early transposon elements, an active family of mouse long terminal repeat retrotransposons.

Authors:  Irina A Maksakova; Dixie L Mager
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

Review 4.  Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming.

Authors:  Rudolf Jaenisch; Richard Young
Journal:  Cell       Date:  2008-02-22       Impact factor: 41.582

5.  Retinoic acid-mediated down-regulation of Oct3/4 coincides with the loss of promoter occupancy in vivo.

Authors:  S Minucci; V Botquin; Y I Yeom; A Dey; I Sylvester; D J Zand; K Ohbo; K Ozato; H R Scholer
Journal:  EMBO J       Date:  1996-02-15       Impact factor: 11.598

6.  Regulation of Oct-4 gene expression during differentiation of EC cells.

Authors:  J Schoorlemmer; L Jonk; S Sanbing; A van Puijenbroek; A Feijen; W Kruijer
Journal:  Mol Biol Rep       Date:  1995       Impact factor: 2.316

Review 7.  Minireview: the diverse roles of nuclear receptors in the regulation of embryonic stem cell pluripotency.

Authors:  Ryan T Wagner; Austin J Cooney
Journal:  Mol Endocrinol       Date:  2013-03-15

8.  Functional Divergence of the Nuclear Receptor NR2C1 as a Modulator of Pluripotentiality During Hominid Evolution.

Authors:  Jennifer L Baker; Katherine A Dunn; Joseph Mingrone; Bernard A Wood; Beverly A Karpinski; Chet C Sherwood; Derek E Wildman; Thomas M Maynard; Joseph P Bielawski
Journal:  Genetics       Date:  2016-04-13       Impact factor: 4.562

9.  The POU homeodomain protein OCT3 as a potential transcriptional activator for fibroblast growth factor-4 (FGF-4) in human breast cancer cells.

Authors:  Peixiang Wang; Donald R Branch; Meenakshi Bali; Gilbert A Schultz; Paul E Goss; Tianru Jin
Journal:  Biochem J       Date:  2003-10-01       Impact factor: 3.857

10.  Retinoic acid accelerates downregulation of the Xist repressor, Oct4, and increases the likelihood of Xist activation when Tsix is deficient.

Authors:  Janice Y Ahn; Jeannie T Lee
Journal:  BMC Dev Biol       Date:  2010-08-20       Impact factor: 1.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.